Total trials
364
Active
170
Phase 3
14
Total enrollment
429,847
Pipeline matrix
Showing 40 of 138 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide | — | — | — | 4 | |||
| Propofol | — | — | — | — | 9 | ||
| Remimazolam | — | — | — | — | 8 | ||
| Ciprofol | — | — | — | — | 3 | ||
| Methylprednisolone | — | — | — | — | — | 2 | |
| Trimethoprim/Sulfamethoxazole | — | — | — | — | — | 1 | |
| Immunosuppressant other than CYC | — | — | — | — | — | 1 | |
| Telitacicept Freeze-dried powder Injection 80mg | — | — | — | — | — | 1 | |
| PD-1,PD-L1 | — | — | — | — | — | 1 | |
| Secukinumab 300mg s.c. | — | — | — | — | — | 1 | |
| Secukinumab 150mg s.c. | — | — | — | — | — | 1 | |
| Ivarmacitinib | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| Jinfeng Pill | — | — | — | — | — | 1 | |
| Donafenib | — | — | — | — | 2 | ||
| Sintilimab | — | — | — | — | 6 | ||
| Cisplatin | — | — | — | — | 5 | ||
| Bevacizumab | — | — | — | — | 5 | ||
| Lenvatinib | — | — | — | 5 | |||
| Camrelizumab | — | — | — | — | 3 | ||
| Carboplatin | — | — | — | 3 | |||
| Nab paclitaxel | — | — | — | — | 3 | ||
| Paclitaxel | — | — | — | — | 2 | ||
| SHR-A1811 | — | — | — | — | 2 | ||
| Chemotherapy | — | — | — | 3 | |||
| Hydroxychloroquine | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| QL1706 | — | — | — | — | — | 1 | |
| Fluzoparib Monotherapy | — | — | — | — | — | 1 | |
| Glimepiride | — | — | — | — | — | 1 | |
| Diammonium glycyrrhizinate | — | — | — | — | — | 1 | |
| Cadonilimab | — | — | — | — | — | 2 | |
| Adebrelimab | — | — | — | — | — | 2 | |
| Paclitaxel-albumin | — | — | — | — | — | 2 | |
| Fludarabine | — | — | — | — | 2 | ||
| Lenvatinib plus pucotenlimab | — | — | — | — | — | 2 | |
| dalpiciclib | — | — | — | — | — | 1 | |
| CD33/CD123/CLL-1 CAR-T Cells | — | — | — | — | — | 1 | |
| Gemcitabine + Cisplatin | — | — | — | — | — | 1 |
98 more active programs hidden
Next readouts
- 2023-09-25
- 2023-11-01
- 2024-09-01
- 2024-11-01
- 2024-12-31
- 2025-05-01
- 2025-06-01
- 2025-06-01
- 2025-06-30
- 2025-11-30
Top conditions
- Ovarian Cancer13
- Hepatocellular Carcinoma9
- HCC7
- Hepatocellular Carcinoma (HCC)7
- Cervical Cancer7
- COVID-196
- Surgery5
- Breast Cancer4
Frequently asked questions about Tongji Hospital
- How many clinical trials does Tongji Hospital have on ClinicalTrials.gov?
- Tongji Hospital is listed as the lead sponsor on 364 clinical trials in ClinicalTrials.gov, 170 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Tongji Hospital's trials are in Phase 3?
- 14 of Tongji Hospital's trials are in Phase 3, spread across 138 active drug programs.
- What therapeutic areas does Tongji Hospital focus on?
- Tongji Hospital's most-studied conditions on ClinicalTrials.gov are Ovarian Cancer, Hepatocellular Carcinoma, HCC, Hepatocellular Carcinoma (HCC), Cervical Cancer.
- When are Tongji Hospital's next clinical trial readouts?
- Tongji Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer”, expected around 2023-09-25.